

Supplemental Table 1. Prevalence of anti-HCV drug resistant mutations (%)

Patient #		1		2		3		4	
Position	Drugs	Liver	Serum	Liver	Serum	Liver	Serum	Liver	Serum
Core mutations related to interferon sensitivity									
Core70 (Arg)	Interferon	0.54	0.26	1.95	0.92	0.28	5.64	0.44	0.32
Core91 (Met)	Interferon	0.07	0.04	98.66	98.27	0.84	0.33	0	0
Resistant mutation to NS3/4A protease inhibitor									
T54S/A	Telaprevir Boceprevir	0.18	0.48	0.11	0.81	0.21	0.17	0.52	0.10
V55A	Boceprevir	0.06	0.24	0.34	0.32	0.36	0.22	0.55	0
Q80R/K	TMC435350	0.38	0.54	0.29	0.27	0.21	0.12	0.28	0.21
V36A/M	Telaprevir Boceprevir	0.27	0.12	0.80	0.28	0.14	0.32	0.31	0.13
V170A/T	Boceprevir	0.07	0.17	0.51	0.18	0.27	0.22	0.84	0.24
A156T/V	Telaprevir	0.16	0.25	0	0.25	0.18	0.13	0.23	0.23
R155K/T/Q	Telaprevir Boceprevir Vaniprevir TMC435350 BI-201335 ITMN191/R7227	0.11	0.05	0.18	0.25	0.09	0.22	0.03	0.12
A156S	Telaprevir Boceprevir	0.05	0	0	0	0.09	0.20	0	0
D168A/V/T/H	Vaniprevir TMC435350 BI-201335 ITMN191/R7227	0	0	0	0.06	0.26	0.08	0.03	0
Resistant mutation to NS5B polymerase inhibitor									
V499A	BI-207127	0.23	0.51	0.40	0.18	0.47	0.23	0.33	0.20
M423T/I/V	Filibuvir	0.76	0.70	0.76	0.68	0.51	0.30	0.67	0.23
P495S/L/A/T	BI-207127	0.23	0.45	0.22	0.34	0.84	0.16	0.25	0.21
P496A/S	BI-207127	0	0.22	0.17	0.21	0.13	0.08	0.04	0.20
S282T	R7128	0	0	0	0	0	0	0	0

Supplemental Table 1. Prevalence of anti-HCV drug resistant mutations (%)

The values in the table indicate the frequency of the mutated HCV clones (%) in the liver and serum in the same patient at the sites of the reported mutations that are related to the efficacy of interferon treatment and drug-resistance against HCV protease and polymerase inhibitors.